Softwr

Research · head to head

Form Bio vs LatchBio

Form Bio logo

Form Bio

Research

Computational platform for cell and gene therapy design and manufacturability

From
On request
Rated
-
Full reviewWebsite
LatchBio logo

LatchBio

AI

AI agents that run bioinformatics analyses, from a company that pivoted from workflow hosting

From
On request
Rated
-
Full reviewWebsite

The short version

  • Each has a real cost: Form Bio the company has pivoted twice since spinning out of Colossal Biosciences in 2022, from general computational life sciences to cell and gene therapy and then to AAV manufacturability, so any evaluation more than a year old describes a product that is no longer the commercial focus.; LatchBio the company has pivoted from hosted bioinformatics workflows to AI agents, so organisations that adopted the earlier SDK and workflow product are now on a line that is no longer the strategic focus.
  • They diverge on capability: Form Bio covers FormManufacturing, LatchBio covers Agent driven analysis.
  • Prices and features above were last checked on 31 August 2026.

Where they differ

Only the attributes on which Form Bio and LatchBio actually diverge.

Attributes where Form Bio and LatchBio differ
AttributeForm BioLatchBio
PlatformsWeb, CloudWeb
CategoryResearchAI

Identical on both: starting price (On request), pricing model (quote), free tier (No), user rating (Not yet rated).

What each one covers

Drawn from each product's published feature list. An absence here means we hold no record of it - not that the product lacks it.

Only in Form Bio

  • FormManufacturing
  • Payload design optimisation
  • Genome integrity analysis
  • Manufacturability prediction
  • In silico workflows
  • Scale-up monitoring
  • Cell and gene therapy focus
  • Collaboration

Only in LatchBio

  • Agent driven analysis
  • Multi assay support
  • Published benchmarks
  • White labelled portals
  • Common file format handling
  • Managed compute

What people use each for

The jobs each tool is most often brought in to do.

Form Bio

  • A gene therapy developer discovering manufacturability problems with an AAV construct late in process development and wanting to move that analysis earliernot LatchBio
  • A biotech comparing several candidate payload designs in silico before committing to expensive production runsnot LatchBio
  • A CDMO characterising what a client construct actually produces against what was specifiednot LatchBio
  • A programme team needing genome integrity evidence to support regulatory conversations about product consistencynot LatchBio

LatchBio

  • A small biotech with sequencing data and no bioinformatician who needs a first pass differential expression or cell type annotation quicklynot Form Bio
  • An assay or kit vendor that wants to give customers an analysis portal under its own branding rather than shipping raw filesnot Form Bio
  • A wet lab scientist who wants to explore a dataset interactively before commissioning a formal analysis from a core facilitynot Form Bio
  • A research group benchmarking agent produced analyses against its own established pipeline to decide how much routine work can be delegatednot Form Bio

Where each one falls short

Documented limitations, not opinions. Every one is a constraint you would hit in normal use.

Form Bio

  • The company has pivoted twice since spinning out of Colossal Biosciences in 2022, from general computational life sciences to cell and gene therapy and then to AAV manufacturability, so any evaluation more than a year old describes a product that is no longer the commercial focus.
  • The current offering launched AAV-focused, so developers working in lentiviral, mRNA or cell therapy modalities are outside the scope the platform was built and validated for.
  • No pricing is published and engagements are scoped per programme, which makes it impossible to size the commitment before entering a sales process.
  • This is a young venture-funded company whose analyses feed regulatory-facing decisions, so continuity of the vendor over a multi-year development programme is a genuine diligence question rather than a formality.
  • Predictive manufacturability models need real production data to be trustworthy, and the value depends on how much of that a young vendor has accumulated, which is difficult for a buyer to verify independently.

LatchBio

  • The company has pivoted from hosted bioinformatics workflows to AI agents, so organisations that adopted the earlier SDK and workflow product are now on a line that is no longer the strategic focus.
  • Agent generated analysis code has to be validated by someone who could have written it, which inverts the value proposition for the small labs that most need it and cannot check the output.
  • No pricing is published, so the cost of routine agent analysis at team scale cannot be estimated without contacting sales, and compute billed through the platform makes the bill usage dependent.
  • Regulated use is a poor fit: an agent that writes non deterministic analysis code is difficult to validate under GxP, so this is a research tool rather than something that will sit in a regulated diagnostic or submission workflow.
  • The vendor publishes its own benchmarks, which is more than most competitors do, but self reported benchmarks on selected datasets are not a substitute for testing the agent on your own data before committing.

Pricing, plan by plan

Form Bio

On request
  • FormManufacturing$undefined/year
    • Pricing only through a sales process
    • Scoped per therapeutic programme rather than per seat
    • AAV-focused offering at launch

LatchBio

On request
  • LatchBio Platform$undefined/year
    • Quoted through a sales process
    • Interactive sandbox available for trying the agent before contracting
    • Enterprise and white labelled portal deployments priced separately

Which should you pick?

Choose Form Bio if

  • You need formmanufacturing.
  • You work on Web, Cloud.
  • You also want payload design optimisation.
Form Bio review

Choose LatchBio if

  • You need agent driven analysis.
  • You also want multi assay support.
LatchBio review

Questions people ask

Is Form Bio or LatchBio better?
Neither clearly leads. Form Bio starts at On request and LatchBio at On request, and user ratings are close enough to be indistinguishable. Choose on capability and platform support.
Which is cheaper, Form Bio or LatchBio?
Form Bio starts at On request and LatchBio at On request.
Does Form Bio or LatchBio run on more platforms?
Form Bio runs on Web, Cloud. LatchBio runs on Web.
What is Form Bio best used for?
Form Bio is most often used for a gene therapy developer discovering manufacturability problems with an aav construct late in process development and wanting to move that analysis earlier, a biotech comparing several candidate payload designs in silico before committing to expensive production runs, a cdmo characterising what a client construct actually produces against what was specified, a programme team needing genome integrity evidence to support regulatory conversations about product consistency. Of those, a gene therapy developer discovering manufacturability problems with an aav construct late in process development and wanting to move that analysis earlier and a biotech comparing several candidate payload designs in silico before committing to expensive production runs are not what LatchBio is typically brought in for.
What can Form Bio do that LatchBio cannot?
Form Bio covers FormManufacturing, Payload design optimisation, Genome integrity analysis, Manufacturability prediction. LatchBio covers Agent driven analysis, Multi assay support, Published benchmarks, White labelled portals.

Answered from the vendors’ own pages

Form Bio: What does Form Bio sell now?

FormManufacturing, launched in 2026, an AAV-focused platform for predicting, optimising and monitoring manufacturability of genetic medicines from construct design through scale-up.

LatchBio: Is LatchBio still selling the original workflow platform?

The company is now led by agent.bio and its agent products. Buyers evaluating the older Python SDK workflow platform should confirm current support directly.

Form Bio: Is it still a general bioinformatics platform?

No. It has narrowed from broad computational life sciences tooling to cell and gene therapy, and within that to AAV.

LatchBio: Can I try it before buying?

Yes. There is an interactive sandbox where you can upload data and run the agent before entering a sales conversation.

Form Bio: Where did the company come from?

It spun out of Colossal Biosciences in 2022.

LatchBio: Is it suitable for regulated work?

Not really. Non deterministic agent generated code is hard to validate under GxP, so treat it as a research and exploration tool.

Form Bio: Is pricing published?

No. Engagements are scoped per programme through a sales process.

LatchBio: What data types does it handle?

Single cell RNA sequencing, spatial transcriptomics, epigenomics, proteomics and pharmacology data, ingesting FastQ, H5AD and spreadsheet formats.

Share

Related pages

More on Form Bio

More on LatchBio

Keep looking

Other head to heads